Physician
Flowood Pain Center, LLC
Flowood Pain Center, LLC was paid $1.26M by Medicaid between Apr 2018 and Dec 2024, across 31 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 59% of everything it billed.
33Billing provider infoFLOWOOD PAIN CENTER, LLC
FLOWOOD, MS 39232
FLOWOOD, MS 39232
33aNPI1356848014assigned 04/10/2018
33bProvider typeInterventional Pain Medicine Physician
28Total paid$1.26M
24GClaims45,954
24DCodes billed31
24AFirst – last monthApr 2018 – Dec 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Mississippi
Rank by total paid#2 of 10
Median peer was paid$38K
This provider vs. median33×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,106 | $15K | |
| 2019 | 2,445 | $25K | |
| 2020 | 6,355 | $140K | |
| 2021 | 8,593 | $295K | |
| 2022 | 11,141 | $299K | |
| 2023 | 6,644 | $239K | |
| 2024incomplete | 8,670 | $245K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 59% | 21,019 | 19,121 | $748K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13% | 5,436 | 4,897 | $169K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 8.5% | 5,709 | 5,281 | $107K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 6.8% | 1,521 | 1,326 | $86K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 3.0% | 725 | 657 | $37K |
| 62323 | 2.3% | 493 | 456 | $29K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 1.4% | 144 | 133 | $17K |
| 64493 | 1.3% | 296 | 194 | $16K | |
| 64483 | <1% | 91 | 77 | $9K | |
| 64494 | <1% | 470 | 195 | $7K | |
| 99442 | <1% | 329 | 277 | $6K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,356 | 1,065 | $6K |
19 more codes
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 2,153 | $4K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 123 | $3K |
| 99441 | <1% | 444 | $3K | |
| 64495 | <1% | 87 | $2K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 43 | $2K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 398 | $1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 28 | $1K |
| 62321 | <1% | 38 | $726.33 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 86 | $636.05 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,793 | $504.67 |
| 99406 | <1% | 104 | $494.91 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 1,584 | $345.63 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 971 | $212.17 |
| 64484 | <1% | 14 | $97.98 | |
| 20610 | <1% | 12 | $24.31 | |
| J2704 | Injection, propofol, 10 mg | <1% | 374 | $21.73 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 18 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 80 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGREEN, TERESA (REVENUE MANAGER)
| Provider | Location | Paid |
|---|---|---|
| City of Tacoma | Tacoma, WA | $79.79M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.